Susceptibility of Mice to Trypanosoma evansi Treated with Human Plasma Containing Different Concentrations of Apolipoprotein L-1
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The aim of this study was to test the susceptibility of mice to Trypanosoma evansi treated with human plasma containing different concentrations of apolipoprotein L-1 (APOL1). For this experiment, a strain of T. evansi and human plasma (plasmas 1, 2, and 3) from 3 adult males clinically healthy were used. In vivo test used 50 mice divided in 5 groups (A to E) with 10 animals in each group. Animals of groups B to E were infected, and then treated with 0.2 ml of human plasma in the following outline: negative control (A), positive control (B), treatment with plasma 1 (C), treatment with plasma 2 (D), and treatment with plasma 3 (E). Mice treated with human plasma showed an increase in longevity of 40.9±0.3 (C), 20±9.0 (D) and 35.6±9.3 (E) days compared to the control group (B) which was 4.3±0.5 days. The number of surviving mice and free of the parasite (blood smear and PCR negative) at the end of the experiment was 90%, 0%, and 60% for groups C, D, and E, respectively. The quantification of APOL1 was performed due to the large difference in the treatments that differed in the source plasma. In plasmas 1, 2, and 3 was detected the concentration of 194, 99, and 115 mg/dl of APOL1, respectively. However, we believe that this difference in the treatment efficiency is related to the level of APOL1 in plasmas.
Abstract
The aim of this study was to test the susceptibility of mice to Trypanosoma evansi treated with human plasma containing different concentrations of apolipoprotein L-1 (APOL1). For this experiment, a strain of T. evansi and human plasma (plasmas 1, 2, and 3) from 3 adult males clinically healthy were used. In vivo test used 50 mice divided in 5 groups (A to E) with 10 animals in each group. Animals of groups B to E were infected, and then treated with 0.2 ml of human plasma in the following outline: negative control (A), positive control (B), treatment with plasma 1 (C), treatment with plasma 2 (D), and treatment with plasma 3 (E). Mice treated with human plasma showed an increase in longevity of 40.9±0.3 (C), 20±9.0 (D) and 35.6±9.3 (E) days compared to the control group (B) which was 4.3±0.5 days. The number of surviving mice and free of the parasite (blood smear and PCR negative) at the end of the experiment was 90%, 0%, and 60% for groups C, D, and E, respectively. The quantification of APOL1 was performed due to the large difference in the treatments that differed in the source plasma. In plasmas 1, 2, and 3 was detected the concentration of 194, 99, and 115 mg/dl of APOL1, respectively. However, we believe that this difference in the treatment efficiency is related to the level of APOL1 in plasmas.
참고문헌 (24)
- Silva RAMS, "Trypanosoma evansi e Trypanosoma vivax: biologia diagnóstico e controle", pp.166~ (2002), Corumbá. Embrapa Pantanal
- Lun ZR, "Desser SS. Is the broad range of hosts and geographical distribution of Trypanosoma evansi attributable to the loss of maxicircle kinetoplast DNA", Parasitol Today, 11, pp.131~133 (1995)
- Hoare CA, "Trypanosomes of mammals: A zoological monograph", pp.749~ (1972), Oxford, UK. Blackwell Publ. Co
- Kubiak GVL, "Tripanosomíase equina (Mal das Cadeiras). Boletim n.33. Instituto de Biologia e Pesquisas Tecnológicas do Estado do Paraná", pp.72~ (1954), Curitiba, Tip. João Haupt & Cia. Ltda
- Joshi PP, "Jannin J, Truc P. Human trypanosomosis caused by Trypanosoma evansi in India: The first case report", Am J Trop Med Hyg, 73, pp.491~495 (2005)
- Shegokar VR, "Short report: Human trypanosomiasis caused by Trypanosoma evansi in a village in India: preliminary serologic survey of the local population", Am J Trop Med Hyg, 75, pp.869~870 (2006)
- Pérez-Morga D, "Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes", Science, 309, pp.469~472 (2005)
- Vanhollebeke B, "Human Trypanosoma evansi infection linked to a lack of apolipoprotein L-I", N Engl J Med, 355, pp.2752~2756 (2006)
- Otto MA, "Tavares KC, Zanette RA, Miletti LC, Monteiro SG. Susceptibility of Trypanosoma evansi to human blood and plasma in infected mice", Vet Parasitol, 168, pp.1~4 (2010)
- Otto MA, "Trypanosoma evansi: therapy with human plasma in infected rats", Comp Clin Pathol, 20, pp.139~141 (2011)
- Colpo CB, "Infecção Natural por Trypanosoma evansi em cão no Rio Grande do Sul", Ciência Rural, 35, pp.717~719 (2005)
- da Silva AS, "Método de contenção e confecção de esfregaço sanguíneo para pesquisa de hemoparasitas em ratos e camundongos", FZVA, 13, pp.83~87 (2006)
- Sambrook J, "Molecular cloning: a laboratory manual. Second edition", pp.300~ (1989), New York. Cold Spring Harbor Laboratory Press
- Ventura RM, "Genetic relatedness among Trypanosoma evansi stocks by random amplification of polymorphic DNA and evaluation of a synapomorphic DNA fragment for species-specific diagnosis", Int J Parasitol, 32, pp.53~63 (2002)
- Tuntasuvan D, "Chemotherapy of surra in horses and mules with diminazene aceturate", Vet Parasitol, 110, pp.227~233 (2003)
- da Silva AS, "Aceturato de diminazeno e dipropionato de imidocarb no controle de infecção por Trypanosoma evansi em Rattus norvegicus infectados experimentalmente", Ciênc Rural, 38, pp.1357~1362 (2008)
- Da Silva AS, "Tripanossomose em equinos na região sul do Brasil", Acta Sci Vet, 38, pp.113~120 (2010)
- Jenings FW, "The relationship between duration of infection with Trypanosoma brucei in mice and the efficacy of chemotherapy", Parasitology, 75, pp.143~153 (1977)
- Spinosa HS, "Farmacologia aplicada à medicina veterinária. Rio de Janeiro", pp.946~ (1999), Guanabara koogan
- Lai DH, "Investigations into human serum sensitivity expressed by stocks of Trypanosoma brucei evansi", Int J Parasitol, 40, pp.705~710 (2010)
- Pays E, "The trypanolytic factor of human serum", Nat Rev Microbiol, 4, pp.477~486 (2006)
- Rifkin MR, "Identification of the trypanocidal factor in normal human serum: high density lipoprotein", Proc Natl Acad Sci USA, 75, pp.3450~3454 (1978)
- Hajduk SL, "Lysis of Trypanosoma brucei by a toxic subspecies of human high density lipoprotein", J Biol Chem, 264, pp.5210~5217 (1989)
- Raper J, "Characterization of a novel trypanosome lytic factor from human serum", Infect Immun, 67, pp.1910~1916 (1999)